CD274 and non-small cell lung carcinoma: Programmed death‐1 (PD‐1), as well as programmed death‐ligand 1 (PD‐L1) inhibitors for the treatment of advanced non‐small cell lung cancer (NSCLC) are currently available and have demonstrated antitumor activity.21